Atossa Therapeutics, Inc. financial data

Symbol
ATOS on Nasdaq
Industry
Pharmaceutical Preparations
Location
10202 5 Th Avenue Ne, Suite 200, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ATOSSA GENETICS INC (to 11/13/2019)
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.47K % -45.4%
Debt-to-equity 7 % +89%
Return On Equity -32.8 % -11%
Return On Assets -30.7 % -7.58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 129M shares +3.09%
Common Stock, Shares, Outstanding 129M shares +3.09%
Entity Public Float 150M USD -6.22%
Common Stock, Value, Issued 23.5M USD +3.05%
Weighted Average Number of Shares Outstanding, Basic 126M shares -0.18%
Weighted Average Number of Shares Outstanding, Diluted 126M shares -0.18%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.1M USD -18.6%
General and Administrative Expense 13.5M USD -3.84%
Operating Income (Loss) -27.6M USD +12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25.5M USD +15.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -25.5M USD +15.3%
Earnings Per Share, Basic -0.2 USD/shares +16.7%
Earnings Per Share, Diluted -0.2 USD/shares +16.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.1M USD -19.6%
Other Assets, Current 7K USD -96.5%
Assets, Current 74.5M USD -19.3%
Other Assets, Noncurrent 1.99M USD -14.5%
Assets 76.4M USD -20.6%
Accounts Payable, Current 679K USD -15.8%
Employee-related Liabilities, Current 1.86M USD +12.6%
Accrued Liabilities, Current 919K USD -5.55%
Liabilities, Current 4.97M USD -5.14%
Liabilities 4.97M USD -5.14%
Retained Earnings (Accumulated Deficit) -212M USD -13.7%
Stockholders' Equity Attributable to Parent 71.5M USD -21.5%
Liabilities and Equity 76.4M USD -20.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.7M USD +33.1%
Net Cash Provided by (Used in) Financing Activities 204K USD
Net Cash Provided by (Used in) Investing Activities -6K USD
Common Stock, Shares Authorized 350M shares +100%
Common Stock, Shares, Issued 129M shares +3.09%
Common Stock, Par or Stated Value Per Share 0.18 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.5M USD +35.9%
Deferred Tax Assets, Valuation Allowance 29.5M USD +19.8%
Deferred Tax Assets, Gross 29.6M USD +19.5%
Depreciation 5K USD +66.7%
Payments to Acquire Property, Plant, and Equipment 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.23M USD +22.8%
Deferred Tax Assets, Operating Loss Carryforwards 15.7M USD +18.4%
Preferred Stock, Shares Issued 582 shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 261M USD +2.06%
Preferred Stock, Shares Outstanding 582 shares 0%
Depreciation, Depletion and Amortization 3K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 47K USD -50%
Share-based Payment Arrangement, Expense 2.29M USD -50.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%